AMRN Up, Continues to Build Excitement around FDA Approval

The results of Amarin’s (NASDAQ:AMRN) pivotal ANCHOR Phase 3 clinical trial are now available electronically through The American Journal of Cardiology and are scheduled for print publication in the October 2012 issue. The publication, titled “Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides,” describes the previously reported results of Amarin’s product candidate AMR101, which met all primary and secondary endpoints. Investors have been counting on FDA approval of AMR101 for some time; the panel is expected to make a decision this Thursday and most predict a near unanimous vote. Citing a leaked website last Friday, many speculate the new drug to be named Vascepa, although the company has made no confirmation and has, in fact, trademarked other names. Shares are up slightly this morning.